40 related articles for article (PubMed ID: 30804126)
1. Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ; Weiss SA
Cancer J; 2020; 26(2):100-107. PubMed ID: 32205533
[TBL] [Abstract][Full Text] [Related]
2. Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.
Stelcer E; Konkol M; Głȩboka A; Suchorska WM
Front Oncol; 2019; 9():775. PubMed ID: 31475117
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers in metastatic castration-resistant prostate cancer].
Miller K
Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
[TBL] [Abstract][Full Text] [Related]
4. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.
Li F; Xiang H; Pang Z; Chen Z; Dai J; Chen S; Xu B; Zhang T
Cancer Med; 2020 Oct; 9(19):7341-7351. PubMed ID: 32452656
[TBL] [Abstract][Full Text] [Related]
5. Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer.
Nieder C; Dalhaug A; Pawinski A
In Vivo; 2019; 33(2):465-468. PubMed ID: 30804126
[TBL] [Abstract][Full Text] [Related]
6. Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement.
Nieder C; Dalhaug A; Pawinski A
In Vivo; 2019; 33(1):229-232. PubMed ID: 30587628
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
[TBL] [Abstract][Full Text] [Related]
9. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
[TBL] [Abstract][Full Text] [Related]
10. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.
Di Nunno V; Gatto L; Santoni M; Cimadamore A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Massari F
Front Oncol; 2018; 8():397. PubMed ID: 30319966
[TBL] [Abstract][Full Text] [Related]
12. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
[TBL] [Abstract][Full Text] [Related]
13. Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancer.
Oertel M; Scobioala S; Kroeger K; Baehr A; Stegger L; Haverkamp U; Schäfers M; Eich HT
Radiat Oncol; 2018 Sep; 13(1):185. PubMed ID: 30241556
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond.
Zainfeld D; Goldkorn A
Cancer Treat Res; 2018; 175():87-104. PubMed ID: 30168118
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
